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DNA-reactive compounds are harnessed for cancer chemotherapy.
Their genotoxic effects are considered to be the main mechanism
for the cytotoxicity to date. Because this mechanism preferentially
affects actively proliferating cells, it is postulated that the cytotox-
icity is specific to cancer cells. Nonetheless, they do harm normal
quiescent cells, suggesting that there are other cytotoxic mecha-
nisms to be uncovered. By employing doxorubicin as a representa-
tive DNA-reactive compound, we have discovered a cytotoxic
mechanism that involves a cellular noncoding RNA (ncRNA) nc886
and protein kinase R (PKR) that is a proapoptotic protein. nc886 is
transcribed by RNA polymerase III (Pol III), binds to PKR, and pre-
vents it from aberrant activation in most normal cells. We have
shown here that doxorubicin evicts Pol III from DNA and, thereby,
shuts down nc886 transcription. Consequently, the instantaneous
depletion of nc886 provokes PKR and leads to apoptosis. In a
short-pulse treatment of doxorubicin, these events are the main
cause of cytotoxicity preceding the DNA damage response in a 3D
culture system as well as the monolayer cultures. By identifying
nc886 as a molecular signal for PKR to sense doxorubicin, we have
provided an explanation for the conundrum why DNA-damaging
drugs can be cytotoxic to quiescent cells that have the competent
nc886/PKR pathway.
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DNA-reactive compounds have been widely used for cancerchemotherapy for a long time. They impair various aspects
of DNA metabolism by alkylating DNA, intercalating into DNA,
interfering with the action of topoisomerases, and evicting his-
tones from DNA (1). All these mechanisms have a preferential
impact on actively proliferating cells that need DNA replication,
which is a basis for cancer-specific cytotoxicity. On this assump-
tion, concern about side effects is confined in a subset of normal
cells that are proliferating. Nonetheless, there are cases in which
DNA-reactive anticancer drugs are toxic to nonproliferating nor-
mal cells (1). This cannot be explained by their intrinsic genotoxic
effect and the underlying mechanism remains to be elusive.
Protein kinase R (PKR) is an interferon-inducible serine/thre-
onine kinase. It is present in most mammalian cells in a latent
state and typically is activated by double-stranded RNA (dsRNA)
(2). Upon binding to dsRNA, PKR undergoes dimerization and
autophosphorylation. The phosphorylated PKR (phospho-PKR)
is an active kinase that phosphorylates eukaryotic initiation fac-
tor 2 α subunit (eIF2α), leading to the shutdown of global protein
synthesis and consequently to apoptosis. However, the PKR
pathway is far more complicated than indicated by the description
above. In addition to dsRNA, PKR is controlled by a number of
cellular and external factors to play critical roles in diverse signaling
pathways including nuclear factor-κB (NF-κB) and p53 (3). As these
cellular pathways are important in determining cell death versus cell
proliferation, PKR is implicated, not surprisingly, in cancer pa-
thology. Dysregulation of PKR-mediated apoptosis is a critical
component in tumor development itself as well as in the resistance
of cancer cells to chemotherapeutic drugs.
Several reports indicated PKR’s role in the cytotoxicity of doxo-
rubicin, a DNA-reactive compound that have been used clinically
for a long time (4–8). PKR seems to be activated by doxorubicin; in
this case, PKR should somehow sense doxorubicin (or a molecular
signal induced by it). However, this mechanism is completely un-
known and is even puzzling, given that doxorubicin induces geno-
toxic stresses in the nucleus, but PKR-mediated apoptotic signaling
occurs mainly in the cytoplasm. Even if doxorubicin provokes PKR
and the resultant apoptosis, the significance of these events is
questionable because doxorubicin’s genotoxic effect will lead to cell
death anyway independently of PKR.
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In this study, we have solved those questions by a noncoding
RNA (ncRNA) that binds to PKR and suppresses its activation (9).
It is nc886 (also known as VTRNA2-1 or pre-miR-886), a 101-
nucleotide (nt)-long ncRNA transcribed by RNA polymerase III
(Pol III) and ubiquitously expressed in normal human tissues. The
expression level of nc886 is elevated in some cancer cells (10, 11)
but is completely silenced by CpG DNA hypermethylation in other
malignancies (12–17). Another interesting feature of nc886 is its
short half-life (∼1 h; refs. 9 and 18), which makes it suitable as a
candidate signaling molecule that quickly responds to stimuli. Here,
we have found nc886 to be the key signaling molecule that links a
DNA-reactive compound and PKR to therapeutic apoptosis.
Results
PKR Contributes to Doxorubicin-Induced Apoptosis. Doxorubicin has
been shown to provoke the PKR pathway (4–8). In the case of
human cells, the experimental evidence has been mostly based on
knockdown (KD) experiments by using small interfering (or hair-
pin) RNA (siRNA or shRNA) against PKR. We confirmed this
with PKR knockout (KO) cells that were generated from a thyroid
cell line Nthy-ori 3-1 and a hepatocarcinoma cell line Huh7.5 by
the CRISPR-Cas technique (10) (Fig. 1A and SI Appendix, Fig.
S1A). Doxorubicin treatment induced apoptotic marker proteins,
such as caspase-3 and cleaved Poly (ADP ribose) polymerase
(PARP) in parental Nthy-ori 3-1 cells [PKR wild type (WT)], but
this induction was significantly attenuated in PKR KO cells (Fig.
1A). The comparable induction of p53 and Chk2 (whose phospho-
forms are indicators for DNA damage, Fig. 1A) in PKR WT and
KO cells ascertained that doxorubicin’s genotoxic effect was
equally efficient between them and that our apoptosis data could
not be attributed to a difference in a DNA damage response. In
MTT cell proliferation assays, PKR KO cells were more resistant to
doxorubicin than PKR WT cells (Fig. 1B and SI Appendix, Fig.
S1B). We also performed siRNA-mediated KD of PKR in another
cell line, HCT116 from colon cancer, and observed a higher IC50
value in PKR KD than control KD (SI Appendix, Fig. S2), similarly
to PKR KO data.
Doxorubicin Results in PKR Activation. The above data corroborated
that PKR contributes to doxorubicin-induced apoptosis (4–8). Be-
cause PKR induces apoptosis when activated (2), we presumed
PKR activation upon doxorubicin treatment. However, astonish-
ingly there was no induction of PKR phosphorylation at Thr446, a
representative marker for active PKR, in our Nthy-ori 3-1 and
HCT116 data (Fig. 1 A and C). To rule out technical issues such as
our Western blot procedure or antibody quality, we included a
sample treated with Poly(I:C), a known PKR activator, and repeated
phospho-PKR Western blot. Of eight antibodies tested, none of
them yielded a legitimate band in doxorubicin-treated samples, al-
though three detected phosphorylation at Thr446 or Thr451 in the
Poly(I:C)-treated sample (SI Appendix, Fig. S3A). Of note, eIF2α
phosphorylation was seen both in doxorubicin and Poly(I:C) samples
at a similar level (SI Appendix, Fig. S3B). Having this puzzling result,
we carefully assessed the experimental data in previous literatures
and found that those literatures did not provide phospho-PKR
Western blot as concrete data (elaborated in SI Appendix, Fig.
S3 legend).
One conceivable scenario is that PKR per se, not as an active
form, is required for doxorubicin-induced apoptosis. However, we
disfavored this possibility because eIF2α was phosphorylated (Fig.
1C and SI Appendix, Fig. S3B) and NF-κB was activated in our
luciferase reporter assays employing the NF-κB–responsive pro-
moter (Fig. 1D). These two events represent the canonical down-
stream pathways of active PKR (3). Furthermore, the NF-κB
induction upon doxorubicin treatment was negated by the PKR
inhibitor 2-aminopurine (2-AP), convincingly showing PKR de-
pendency (Fig. 1D). So, we questioned whether the Western blot of
phospho-Thr446 (or Thr451) is a valid indicator in the context of
doxorubicin treatment. Thr446 or Thr451 is not the sole residue
that undergoes phosphorylation but several other Ser/Thr and also
Tyr residues have been identified to be phosphorylated (19, 20).
Therefore, we performed an in vitro kinase assay to measure the
overall autophosphorylation level. A radiolabeled phospho-PKR
was immunoprecipitated and resolved on a SDS-polyacrylamide
gel (Fig. 1 E and F). The asterisked band is PKR, because it mi-
grated at the correct position and was not detectable in PKR KO
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Fig. 1. Activation of PKR by doxorubicin and its contribution to the doxorubicin cytotoxicity. (A) Western blot of indicated proteins after doxorubicin (Doxo)
treatment. Molecular size markers in kilodaltons (kDa) are indicated on the right. (B) MTT cell proliferation assays. Doxorubicin was treated for 24 h. Each data point
is an average of triplicate samples. SDs are not shown because they are small (ranging 0.010∼0.030) and obscured by markers in most data points. (C) Western blot
of indicated proteins as in A. (D) Luciferase assays measuring NF-κB activity. Luciferase-expressing plasmids (the firefly luciferase from the NF-κB–responsive pro-
moter and the Renilla luciferase from the constitutive the SV40 promoter for normalization) were transfected. At 24 h after transfection, cells were pretreated with
2-AP (2 mM) for 1 h and then replaced with a culture medium containing doxorubicin (6 μM) for 8 h. Firefly values (“Pp”) were divided by Renilla values (“Rr”), and
the value of untreated HCT116 was set as 1. (E and F) In vitro kinase assay. The autoradiogram (Upper) and PKR Western (Lower) for equal IP efficiency are shown.
Asterisks indicate the PKR band. (G) Luciferase assays, as described in D, except for no treatment of 2-AP.
8290 | www.pnas.org/cgi/doi/10.1073/pnas.1814510116 Kunkeaw et al.
Nthy-ori 3-1 cells (Fig. 1F). Importantly, PKR phosphorylation was
increased when treated with doxorubicin. The NF-κB luciferase
data in Nthy-ori 3-1 cells were in line with the in vitro kinase assay
data; the NF-κB promoter activity was elevated by doxorubicin in
PKR WT cells, but was lower and unresponsive to doxorubicin in
PKR KO cells (Fig. 1G).
Doxorubicin Suppresses nc886 Expression. So far we proved that
doxorubicin activates PKR. We found a report that doxorubicin
inhibits Pol III that transcribes nc886 (21). Our previous study
has shown that nc886 is a suppressor of PKR activity (22). All of
these inspired us to explore a role of nc886 herein. When treated
with titrating amounts of doxorubicin, nc886 disappeared almost
completely at or above 3 μM (Fig. 2A). It should be noted that
the micromolar range was not unreasonably high compared with
clinically relevant concentrations ranging from 5 to 25 μM (23).
In our time-course experiments, nc886 was noticeably diminished
after 2 h of treatment and was barely seen after 4–8 h in all cell
lines we tested (Fig. 2 B and C and SI Appendix, Fig. S4). At these
time points, cell proliferation was decreased only modestly (SI
Appendix, Fig. S5), indicating that nc886 decreased before doxo-
rubicin elicited its toxic effect on cells. After 8 h, nc886 expression
disappeared completely and did not recover after doxorubicin
removal (Fig. 2B). Our consistent data across cell lines of diverse
tissues origins (colon, thyroid, breast, esophagus, stomach, and
lung) suggest that the suppression of nc886 expression by doxo-
rubicin is a ubiquitous phenomenon. nc886 was not decreased by
an oxidative stress- or a hypoxia-inducing drug (SI Appendix, Fig.
S6), indicating that the doxorubicin effect on nc886 was not simply
an end result of any stress condition.
nc886 Suppression Is the Critical Event for Doxorubicin Cytotoxicity
Through PKR Activation. Thus far we have demonstrated concretely
that doxorubicin treatment results in PKR activation and also in the
suppression of nc886. nc886 is physically associated with PKR (9,
22) (SI Appendix, Fig. S7). Since nc886 inhibits PKR (24), we hy-
pothesized that nc886 suppression is the mechanism for doxorubicin-
mediated PKR activation. To prove this hypothesis, we conducted
several experiments.
We began by examining whether depletion of nc886 elicits the
same cellular response to doxorubicin, by performing nc886 KD
using modified antisense oligonucleotides (anti-oligo). The nc886
targeting anti-oligo (anti-nc886) efficiently suppressed nc886
(Northern blot in Fig. 2D) and led to PKR activation (in vitro ki-
nase assay in Fig. 2D). nc886 KD was sufficient to induce apoptosis
and to inhibit cell proliferation in PKR WT Nthy-ori 3-1 and
HCT116 cells, but not in PKR KO Nthy-ori 3-1 cells (Fig. 2D),
assuring that they occurred through PKR. Collectively, nc886 KD
emulated doxorubicin’s cytotoxicity through PKR activation.
Doxorubicin causes pleiotropic effects. So we wanted to dis-
cern nc886’s contribution and interrogated whether doxorubicin-
mediated cytotoxicity was mitigated by ectopic expression of nc886.
As a Pol III transcript, nc886 expression is driven by gene-internal
promoter elements and, therefore, its expression from an exoge-
nous DNA was also inhibited by doxorubicin (shown later in SI
Appendix, Fig. S17). So, our tactic was to deliver nc886 in a form of
an in vitro transcript. Doxorubicin-induced apoptosis was attenu-
ated when the nc886 transcript was transfected into PKRWT cells,
whereas such attenuation was not seen in PKR KO cells (Fig. 2E
and SI Appendix, Figs. S8 and S9). The role of nc886 on PKR was
confirmed by testing a mutant nc886 (“mut_46-56”) that is de-
ficient in PKR binding (22) (Fig. 2F). Doxorubicin-induced apo-
ptosis was not mitigated by mut_46-56 (Fig. 2G). This result was
further corroborated by a vault RNA (vtRNA), which is a paralog
of nc886 but does not bind to PKR (22). A vtRNA did not mitigate
the apoptosis either (vtRNA1-1 in Fig. 2H). One of nc886’s aliases
is vtRNA2-1, which implies that nc886 might be a component of
the vault complex, which has been implicated in cancer drug
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resistance (25). However, the vault complex did not contain nc886
nor affected doxorubicin sensitivity (SI Appendix, Figs. S10–S13). In
the doxorubicin-induced PKR activation, a role of p53 has been
suggested but remained unclear due to conflicting results between
studies (8, 26). In our data employing p53 WT and null HCT116
cells, p53 barely affected the nc886/PKR pathway (SI Appendix, Fig.
S14). All of our data unequivocally demonstrated that nc886 sup-
pression is a key event for PKR activation and apoptosis in response
to doxorubicin, regardless of the vault complex or the p53 status.
Doxorubicin Inhibits Pol III Transcription. Next, we investigated the
mechanism for nc886 suppression by doxorubicin. A classic study
had shown that doxorubicin inhibits Pol III transcription when
introduced into in vitro transcription assays (21). Pol III transcribes
medium-sized ncRNAs, many of which are stable and abundant
RNAs with fundamental cellular roles (designated collectively as
“Pol III genes”; see Fig. 3A and Dataset S1). Upon doxorubicin
treatment, the expression of most Pol III genes was decreased with
varying degrees (Fig. 3A and SI Appendix, Figs. S15 and S16). The
kinetics of nc886 reduction indicated that its transcription was shut
down almost immediately by doxorubicin, given that nc886’s half-
life is ∼1 h (9, 18). This notion was corroborated by measurement of
two precursor tRNAs (pre-tRNAs), which disappeared within an
hour (SI Appendix, Fig. S16 N and P). Pre-tRNAs are regarded
as the most sensitive indicator to assess Pol III transcription
rates, because they are processing intermediates. Collectively,
Pol III transcription appeared to be inhibited readily upon
doxorubicin treatment. It should be underscored that most Pol
III genes were not so severely (<twofold) affected until 4 h (Fig.
3A and SI Appendix, Figs. S15 and S16), when doxorubicin had
already elicited PKR-dependent apoptosis (Fig. 1A).
The next question was the detailed mechanism for doxorubicin
to inhibit Pol III. Doxorubicin belongs to the anthracycline family
consisting of flat aromatic moieties and imposes stresses on DNA/
chromatin in multiple ways. It intercalates into DNA to generate
topological tension. Another well-known effect is topoisomerase
II (topo II) poisoning by trapping of topo II in the double-strand
cleavage form and preventing ligation (27). The cellular outcomes
of these effects are DNA strand breakage, eviction of histones
from chromatin, and DNA damage responses. To discern which
event is causative of the suppression of Pol III transcription, we
compared three different compounds (Fig. 3B). Aclarubicin is an
anthracycline compound and is a DNA intercalator. However, it is not a
topo II poison unlike doxorubicin (27). Etoposide, a nonanthracycline
compound, does not intercalate into DNA but acts as a topo II
poison (27).
At therapeutic doses (23, 28), doxorubicin and aclarubicin sup-
pressed nc886 expression, whereas etoposide did not (Fig. 3B). In
all three drugs, phosphorylation of p53 and Chk2 was seen (Fig.
3B), indicating that all treatments were effective and, more im-
portantly, that nc886 suppression was not due to the aftermath of
DNA damage responses. Our etoposide data proved that the sup-
pression of Pol III transcription was not caused by topo II poisoning
(or the resultant DNA breakage). Our data from linear and circular
plasmid DNAs also suggested that Pol III inhibition by doxorubicin
was not caused by intercalation into DNA and the resultant DNA
torsion (SI Appendix, Fig. S17) either.
Because doxorubicin and aclarubicin, but not etoposide, are
known to evict histones (29, 30), we surmised that these two drugs
would lead to Pol III dissociation from DNA. To directly test this
idea, we examined bound DNA to POLR3A, the catalytic subunit
of Pol III enzyme, by chromatin immunoprecipitation followed by
high-throughput sequencing (ChIP-seq) (31). A POLR3A peak
was present at the correct position at nc886 and other Pol III loci,
but absent in a Pol II gene GAPDH (Fig. 3C and SI Appendix, Fig.
S18). Importantly, the peaks in all of the Pol III loci disappeared
upon doxorubicin treatment. In the human genome, there are 4,553
Pol III loci that were curated in our previous study (18). When we
analyzed the ChIP-seq data comprehensively in these loci (Dataset
S1), we found global dissociation of POLR3A to occur upon
doxorubicin treatment, as indicated by the number of POLR3A-
bound loci (Fig. 3D) and the intensity of POLR3A signal estimated
from seq reads (Fig. 3E and SI Appendix, Fig. S16). ChIP-seq data
were reconfirmed by ChIP-PCR (SI Appendix, Fig. S19). Collec-
tively, doxorubicin evicts Pol III from DNA.
A Short Pulse Doxorubicin Treatment Provokes the nc886/PKR
Pathway but Not DNA Damage Response. Collectively from our
data, it appears that the transcription of nc886 was shut down im-
mediately upon doxorubicin treatment (Figs. 2 and 3) and was not
resumed after removal of doxorubicin afterward (Fig. 2B). Hence, a
short pulse treatment might be sufficient to activate the nc886/PKR
pathway and apoptosis. We tested this possibility by treating cells
with doxorubicin and replacing the medium with a doxorubicin-free
medium at 15, 30, and 60 min (Fig. 4A). The 30-min pulse of
doxorubicin was enough to suppress nc886 and induce apoptosis in
a PKR-dependent manner at 4 h (Fig. 4B) but was too short to
induce the DNA damage response as measured by phospho-Chk2
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Fig. 3. The eviction of Pol III and inhibition of transcription
by doxorubicin. (A) Expression levels of Pol III genes at 4 h
after doxorubicin treatment, relative to 0 h, which is des-
ignated as “control (-Doxo)”. Full data and detailed de-
scription are in SI Appendix, Figs. S15 and S16. (B) Northern
(Left) and Western (Right) blot after 8 h-treatment of
aclarubicin (Acla; 6 μM), etoposide (Etopo; 30 μM), and
doxorubicin (Doxo; 6 μM), as well as no treatment control
(the leftmost lane). Features of the three drugs are briefly
summarized at the bottom of the Northern blot. (C) The
POLR3A ChIP-seq peak of nc886. Ten million tags were used
for normalization of relative POLR3A signal from ChIP-seq
reads. The normalized ChIP-seq density (y axis) is shown
along the genomic coordinate (hg19) of nc886 and its
flanking 1-kb region at both sides (x axis). IGV 2.3 was used
for visualization. (D) Number of POLR3A-occupied Pol III
loci. (E) A boxplot of normalized POLR3A occupancy per
each locus. The ANOVA test was used to calculate P values.
8292 | www.pnas.org/cgi/doi/10.1073/pnas.1814510116 Kunkeaw et al.
(Fig. 4B). So we found a doxorubicin treatment condition in which
the nc886/PKR pathway, rather than the DNA damage response,
dominantly operated to induce apoptosis.
The nc886/PKR Pathway Is Effective also in the 3D Cell Culture System.
So far, our experiments were performed in the conventional 2D
monolayer cell culture, which is significantly different from the in
vivo tumor environment in many aspects including drug sensitivity.
Since cells cultured in 3D show features closer to in vivo physiology
(32), we attempted to examine doxorubicin’s effect on nc886 and
apoptosis in a 3D culture by using a recently developed protocol. In
this technique (33), cells were coated with magnetic nanoparticles
and levitated by applying a magnetic field. The levitated cells
formed a 3D structure with extracellular matrix and were bioprinted
onto a plate (Fig. 4C). Doxorubicin, both in continuous and pulse
treatments to a 3D culture, suppressed nc886 and induces apoptosis
(Fig. 4 D and E).
Epigenetic Silencing of nc886 Is Related to Cellular Resistance to
Doxorubicin. nc886 expression is silenced by the promoter CpG
hypermethylation in a subset of cancer cells (9, 11–15, 18, 34). To
implicate this phenomenon in our experimental data here so far,
we downloaded doxorubicin IC50 values of 931 cell lines from a
cancer drug database (https://www.cancerrxgene.org/) and also
obtained CpG methylation values in 957 cell lines from a pub-
lished study (35). Comparison of the two datasets yielded 791 cell
lines with both values (Dataset S2). We sorted IC50 values in as-
cending order, plotted (Fig. 4F), and found only 27 cell lines to
have IC50 > 6 μM (3.4% of 791 cell lines), the concentration used
in most of our experiments here. In a lower IC50 cutoff (1.5 μM),
83 cell lines (10.5%) met this criterion. In addition, a majority of
tumors that have acquired doxorubicin resistance also had IC50
values < 6 μM (SI Appendix, Fig. S20 and Dataset S3).
As aforementioned, epigenetic silencing of nc886, which is an
intriguing and unique feature among Pol III genes (reviewed in ref.
36), occurs in some cancer cells. In theory and also based on our
data here, this silencing should have resulted in cell death, because
PKR should have been activated. However, nc886-silenced in vitro
cell lines and in vivo tumor cells do exist. Our previous studies (15,
37) elucidated this by a tumor surveillance model. In this model,
such cell death would have occurred to ensure the elimination of
precancerous cells, which would have contributed to the lowering of
a cancer incidence rate. However, certain cells acquire genetic/epi-
genetic alterations, for example overexpression of eIF2B that neu-
tralizes the apoptotic effect of phospho-eIF2α, to bypass the PKR
cell death pathway (15). Only those cells could have survived upon
nc886 silencing and developed into clinically detectable and in vitro
isolatable malignant cells. We hypothesized that those cells lost the
PKR pathway for cell death and therefore tended to be resistant to
doxorubicin, especially at micromolar concentrations. Because
nc886 is a not a microRNA nor mRNA, it is challenging to estimate
its expression level from public array or sequencing data. Therefore,
we looked into CpG methylation values as a proxy indicator for
nc886 silencing. nc886 has a CpG island (−189 to +82, as the 5′-end
of the nc886 transcript being the +1 reference point), and we ana-
lyzed 10 CpG sites within or close to this island. We calculated an
average of the 10 sites and regarded >90% to be hypermethylation.
In this analysis (pie charts in Fig. 4F) only 86 of 632 doxorubicin-
sensitive (IC50 < 0.6 μM) cell lines were nc886-hypermethylated
(12.0%). When we did the same analysis in doxorubicin-resistant
(IC50 > 1.5 μM) cell lines, we observed a significant enrichment of
hypermethylated cells (20 of 83; 19.4%). These data supported our
idea that the PKR cell death pathway has become defective in
nc886-silenced cells, which is a contributing factor for their resistance
to doxorubicin.
Discussion
In this study, we have found that nc886/PKR signaling is another
important pathway in the cytotoxicity of doxorubicin. Our data
clearly demonstrated that doxorubicin decreases nc886, thereby
activates PKR, and leads to apoptosis. This is a signal transduction
pathway in which a genotoxic stress in the nucleus is transmitted to
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a cytoplasmic protein through an ncRNA. Also, our finding calls a
need to reconsider the long-standing tenet that DNA-reactive com-
pounds are selectively toxic to proliferating cells, since nc886 and
PKR are expressed in most normal cells regardless of cell pro-
liferation (3, 9).
Our data would be applicable to improve the therapeutic regimen
for doxorubicin (and probably all anthracycline drugs) by consid-
ering the nc886/PKR mechanism. When we want to exploit doxo-
rubicin’s original genotoxic role to kill cancer cells, combination
with a PKR inhibitor is a reasonable formulation to minimize a
collateral damage to quiescent normal cells. Alternatively, we
could use the nc886/PKR pathway as a target to kill tumor cells.
Although one would suspect whether this strategy harms normal
cells as well, we anticipate that doxorubicin could trigger the
nc886/PKR pathway in tumor cells more proficiently, because
the nc886 expression level is high and PKR activity is low usually
in tumors compared with normal cells. Global Pol III tran-
scription, accordingly nc886 expression, increases during tu-
morigenesis (reviewed in ref. 38) (9, 10, 18). Due to PKR’s
proapoptotic function, PKR is supposed to be suppressed in
malignancies and it has been shown so in a number of literatures
(reviewed in ref. 39). When targeting nc886/PKR, a short pulse
(30 min) treatment of doxorubicin at a high dose (> several
micromolars) will be sufficient to induce apoptosis, with a min-
imal genotoxic effect adversely on proliferating normal cells such
as cells at the hematopoietic lineage, hair follicle cells, and ep-
ithelial cells of the intestine. Also, it is obvious that this regimen
is inappropriate for nc886-silenced cancer cells.
In addition to DNA-reactive drugs, the PKR pathway also
operates in response to various external stimuli such as deprivation
of growth factors, heat shock, metabolic stress, and biotoxins. Some
PKR upstream regulators, such as PACT/RAX, heat shock pro-
teins, ribosomes, and some cellular ncRNAs are implicated in
conveying these stresses to PKR (reviewed in refs. 40 and 41) (42).
However, stress-sensing mechanisms have not been elucidated yet
in many cases. As mentioned earlier, nc886 has a short half-life and
so can respond quickly to external signals. nc886 can be a potent
PKR regulator given that its binding affinity to PKR is very high
(KD = ∼12 nM, ref. 22) and it is abundantly expressed (105 RNA
molecules per cell, ref. 9). Collectively, nc886 is well suited as a
molecular signal for PKR and we surmise that nc886 plays this role
in other stress conditions besides doxorubicin.
Materials and Methods
Cell lines, antibodies, plasmids, anti-oligos and other reagents are described in
refs. 9, 10, and 15 and in SI Appendix. Sequences for primers (for PCR and
Northern blot) are summarized in Dataset S4. Luciferase assays, cell proliferation
assays, and in vitro kinase assays were performed as described in refs. 9 and 15.
POLR3A ChIP-seq was done as described (18), and the raw files are available (31).
Three-dimensional cell culture was done as described in SI Appendix. Unless
otherwise specified, assays were done in triplicate to calculate an average
and SD.
ACKNOWLEDGMENTS. We thank Drs. Anindya Dutta and Etsuko Shibata
(University of Virginia) for helpful discussion and Drs. Glauco R. Souza and
Kim Brath (n3D Biosciences and Greiner Bio-One) and Ms. Lauren S.
Richardson for assistance with the 3D culture. This work was supported by
National Cancer Center, Korea Grants NCC-1810071-1 (to Y.S.L.) and NCC-
1810072-1 (to I.-H.K.), the Collaborative Genome Program for Fostering New
Post-Genome Industry of the National Research Foundation funded by
Ministry of Science and ICT Grant NRF-2017M3C9A6044517 (to Y.-S.L.), and
Thailand Research Fund Grant MRG5980034 (to N.K.).
1. Cheung-Ong K, Giaever G, Nislow C (2013) DNA-damaging agents in cancer chemo-
therapy: Serendipity and chemical biology. Chem Biol 20:648–659.
2. Garcia-Ortega MB, et al. (2017) Clinical and therapeutic potential of protein kinase
PKR in cancer and metabolism. Expert Rev Mol Med 19:e9.
3. Williams BR (1999) PKR; a sentinel kinase for cellular stress. Oncogene 18:6112–6120.
4. Cheng X, Bennett RL, Liu X, Byrne M, Stratford May W (2013) PKR negatively regu-
lates leukemia progression in association with PP2A activation, Bcl-2 inhibition and
increased apoptosis. Blood Cancer J 3:e144.
5. Bennett RL, et al. (2012) Increased expression of the dsRNA-activated protein kinase
PKR in breast cancer promotes sensitivity to doxorubicin. PLoS One 7:e46040.
6. Peidis P, Papadakis AI, Muaddi H, Richard S, Koromilas AE (2011) Doxorubicin bypasses
the cytoprotective effects of eIF2α phosphorylation and promotes PKR-mediated cell
death. Cell Death Differ 18:145–154.
7. Tu YC, et al. (2012) Blocking double-stranded RNA-activated protein kinase PKR by
Japanese encephalitis virus nonstructural protein 2A. J Virol 86:10347–10358.
8. Yoon CH, Lee ES, Lim DS, Bae YS (2009) PKR, a p53 target gene, plays a crucial role in
the tumor-suppressor function of p53. Proc Natl Acad Sci USA 106:7852–7857.
9. Lee K, et al. (2011) Precursor miR-886, a novel noncoding RNA repressed in cancer,
associates with PKR and modulates its activity. RNA 17:1076–1089.
10. Lee EK, et al. (2016) nc886, a non-coding RNA and suppressor of PKR, exerts an on-
cogenic function in thyroid cancer. Oncotarget 7:75000–75012.
11. Ahn JH, et al. (2018) nc886 is induced by TGF-β and suppresses the microRNA pathway
in ovarian cancer. Nat Commun 9:1166.
12. Jang HJ, et al. (2016) Integrated genomic analysis of recurrence-associated small non-
coding RNAs in oesophageal cancer. Gut 66:215–225.
13. Lee KS, et al. (2014) nc886, a non-coding RNA of anti-proliferative role, is suppressed
by CpG DNA methylation in human gastric cancer. Oncotarget 5:3944–3955.
14. Lee HS, et al. (2014) Epigenetic silencing of the non-coding RNA nc886 provokes
oncogenes during human esophageal tumorigenesis. Oncotarget 5:3472–3481.
15. Kunkeaw N, et al. (2013) Cell death/proliferation roles for nc886, a non-coding RNA,
in the protein kinase R pathway in cholangiocarcinoma. Oncogene 32:3722–3731.
16. Treppendahl MB, et al. (2012) Allelic methylation levels of the noncoding VTRNA2-1
located on chromosome 5q31.1 predict outcome in AML. Blood 119:206–216.
17. Cao J, et al. (2013) DNA methylation-mediated repression of miR-886-3p predicts poor
outcome of human small cell lung cancer. Cancer Res 73:3326–3335.
18. Park JL, et al. (2017) Epigenetic regulation of RNA polymerase III transcription in early
breast tumorigenesis. Oncogene 36:6793–6804.
19. Taylor DR, et al. (1996) Autophosphorylation sites participate in the activation of the
double-stranded-RNA-activated protein kinase PKR. Mol Cell Biol 16:6295–6302.
20. Su Q, et al. (2006) Tyrosine phosphorylation acts as a molecular switch to full-scale
activation of the eIF2alpha RNA-dependent protein kinase. Proc Natl Acad Sci USA
103:63–68.
21. Logan K, Ackerman S (1988) Effects of antibiotics on RNA polymerase III transcription.
DNA 7:483–491.
22. Jeon SH, et al. (2012) Characterization of the direct physical interaction of nc886, a
cellular non-coding RNA, and PKR. FEBS Lett 586:3477–3484.
23. Mross K, et al. (1988) Pharmacokinetics and metabolism of epidoxorubicin and
doxorubicin in humans. J Clin Oncol 6:517–526.
24. Lee YS (2015) A novel type of non-coding RNA, nc886, implicated in tumor sensing
and suppression. Genomics Inform 13:26–30.
25. van Zon A, Mossink MH, Scheper RJ, Sonneveld P, Wiemer EA (2003) The vault
complex. Cell Mol Life Sci 60:1828–1837.
26. Rahman M, Lem C, Muaddi H, Koromilas AE (2009) PKR is not a universal target of
tumor suppressor p53 in response to genotoxic stress. Cell Cycle 8:3606–3607.
27. Nitiss JL (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev
Cancer 9:338–350.
28. Hande KR, et al. (1984) Pharmacokinetics of high-dose etoposide (VP-16-213) ad-
ministered to cancer patients. Cancer Res 44:379–382.
29. Pang B, et al. (2013) Drug-induced histone eviction from open chromatin contributes
to the chemotherapeutic effects of doxorubicin. Nat Commun 4:1908.
30. Yang F, Kemp CJ, Henikoff S (2013) Doxorubicin enhances nucleosome turnover
around promoters. Curr Biol 23:782–787.
31. Song M-J, et al. (2019) Data from “Polymerase III ChIP-seq in HCT116 cell line.” Sequence
Read Archive. Available at https://www.ncbi.nlm.nih.gov/sra/?term=PRJNA522927. De-
posited February 28, 2019.
32. Ravi M, Paramesh V, Kaviya SR, Anuradha E, Solomon FD (2015) 3D cell culture sys-
tems: Advantages and applications. J Cell Physiol 230:16–26.
33. Souza GR, et al. (2010) Three-dimensional tissue culture based on magnetic cell lev-
itation. Nat Nanotechnol 5:291–296.
34. Lee BJ, de la Peña P, Tobian JA, Zasloff M, Hatfield D (1987) Unique pathway of ex-
pression of an opal suppressor phosphoserine tRNA. Proc Natl Acad Sci USA 84:
6384–6388.
35. Iorio F, et al. (2016) A landscape of pharmacogenomic interactions in cancer. Cell 166:
740–754.
36. Park JL, et al. (2017) Epigenetic regulation of noncoding RNA transcription by
mammalian RNA polymerase III. Epigenomics 9:171–187.
37. Jeon SH, Johnson BH, Lee YS (2012) A tumor surveillance model: A non-coding RNA
senses neoplastic cells and its protein partner signals cell death. Int J Mol Sci 13:
13134–13139.
38. Marshall L, White RJ (2008) Non-coding RNA production by RNA polymerase III is
implicated in cancer. Nat Rev Cancer 8:911–914.
39. Marchal JA, et al. (2014) The impact of PKR activation: From neurodegeneration to
cancer. FASEB J 28:1965–1974.
40. García MA, et al. (2006) Impact of protein kinase PKR in cell biology: From antiviral to
antiproliferative action. Microbiol Mol Biol Rev 70:1032–1060.
41. Moon Y (2014) Ribosomal alteration-derived signals for cytokine induction in mucosal
and systemic inflammation: Noncanonical pathways by ribosomal inactivation.
Mediators Inflamm 2014:708193.
42. Youssef OA, et al. (2015) Potential role for snoRNAs in PKR activation during meta-
bolic stress. Proc Natl Acad Sci USA 112:5023–5028.
8294 | www.pnas.org/cgi/doi/10.1073/pnas.1814510116 Kunkeaw et al.
